A world of pharmaceutical trends

Kondro, Wayne
November 2010
CMAJ: Canadian Medical Association Journal;11/23/2010, Vol. 182 Issue 17, pE783
Academic Journal
The article reports on the changes in the global pharmaceutical industry. Novartis AG chief executive officer Joe Jimenez states that the there is a "paradigm shift" taking place in the pharmaceutical industry as a consequence of demographic, economic, and clinical trends. Jimenez adds that the drug sales are dropping worldwide, thus pharmaceutical companies need to explore new development models that present greater patient benefits.


Related Articles

  • 40-a-Day. Clinton, Patrick // Pharmaceutical Executive;Aug2005, Vol. 25 Issue 8, p16 

    Exposes the problem with marketing tactics of pharmaceutical companies. Experience of a pediatrician who encountered a marketing problem with a drug company; Effect on patient-physician trust.

  • GABON: PHARMACEUTICALS & HEALTHCARE REPORT.  // Gabon Pharmaceuticals & Healthcare Report;2014 3rd Quarter, Issue 3, p1 

    The article provides an overview of the performance of the pharmaceuticals and healthcare industry in Gabon for the third quarter of 2014. It highlights the main trends and developments in the country's sector and offers a 10-year forecast for the industry to 2023. It cites the industry risk...

  • How They Fit. Young, Peter // Pharmaceutical Executive;May2007, Vol. 27 Issue 5, p122 

    The article discusses the trends of the global pharmaceutical industry during 2006. A survey from Young & Partners indicated that U.S. pharmaceutical companies had a good year for 2006, while European firms ended up with underperformance on the same period. Meanwhile, pharmaceutical acquisitions...

  • The Russian Psyche.  // Pharmaceutical Executive;May2007, Vol. 27 Issue 5, pS9 

    The article presents several perspectives on the trends of the pharmaceutical industry in Russia. Jostein Davidsen of Nycomed believes that Russia will become one of the top-five European pharmaceutical markets by 2012. In addition, Paul Melling of Baker & McKenzie emphasize that Russia is a...

  • Bupropion: 1 drug, 4 different brand names. Gandey, Allison // CMAJ: Canadian Medical Association Journal;11/25/2003, Vol. 169 Issue 11, p1202 

    Highlights the marketing of bupropion drug under four different names by GlaxoSmithKline in November 2003. Explanation for the marketing strategy; Legal issues involved in renaming a drug; Potential impact of renaming drugs on health care.

  • Drug marketers 'on the alert'. Miller, Cyndee // Marketing News;1/4/1993, Vol. 27 Issue 1, p1 

    The article reports on the impact of the health care system policy reform by U.S. President Bill Clinton on the pharmaceutical industry. Companies will be pressured to keep prices low. It is expected that Clinton's proposed tax credits could boost biotechnology and pharmaceutical companies. The...

  • Editorial.  // Journal of Medical Marketing;Jul2005, Vol. 5 Issue 3, p193 

    Discusses various issues related to pharmaceutical marketing. Arguments pertaining to the meaning of branding in pharmaceutical marketing; View that a brand is a promise, conveying with it a range of attributes and tangible and intangible benefits for the target customer; Discussion on marketing...

  • Marketing basics.  // Pharmaceutical Representative;Jul2005, Vol. 35 Issue 7, p32 

    Discusses the basic aspects of pharmaceutical marketing. Evolution of pharmaceutical marketing; Identification of the four P's of marketing, which refer to product, place, price and promotion; Examination of marketing over the life cycle, market research and the roles of the marketing staff. ...

  • Crunch time: Industry needs to deliver on pipeline. Pajwani, Premal // International Journal of Medical Marketing;Sep2004, Vol. 4 Issue 4, p338 

    The article presents an account of the economic performance of the drug industry in the U.S. and Europe. Drug sector performance has been weak, with U.S. drug stocks underperforming, investors remain wary of drug stocks. The industry's biggest challenge lies in delivering on a robust pipeline of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics